Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

90P - High MICB expression confers prognostic benefit in colorectal cancer

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Shanchao Yu

Citation

Annals of Oncology (2019) 30 (suppl_9): ix30-ix41. 10.1093/annonc/mdz421

Authors

S. Yu

Author affiliations

  • Department Of General Surgery, Zhongshan Hospital - Fudan University, 200032 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 90P

Background

Immune surveillance is closely related to MHC and its associated molecules. The MHC class I chain related B molecule (MICB) is one of the ligands of NKG2D receptor. NKG2D receptor exists in NK cells and CD8+ T cells, which mediate anti-tumor response and immune surveillance. MICB is expressed by intestinal epithelium and epithelial tumors as well. Cancer cells express MICB as the consequence of cellular stress. But tumor cells might develop evasive pathways to avoid NK cell attack. Shedding is a way for cancer cells to remove or avoid the surface expression of MICB. Previous studies haven’t clearly figured out the prognostic value of MICB in colorectal cancer (CRC). Here, we figured out the relationship between MICB and prognosis in a CRC cohort of Zhongshan Hospital. The prognostic benefit was also validated in GSE39582 from Gene Expression Omnibus repository.

Methods

863 consecutive CRC patients from 2008 to 2012 without prior treatment were enrolled. 556 CRC patients between 1987 to 2007 were collected from GSE39582. MICB was detected by immunochemistry. MICB score equaled MICB intensity multiplied by the percentage of positive cells among all tumor cells. The cut-off value of MICB score was calculated by X-tile. The association between clinicopathological features and MICB were accessed by chi-square test. Kaplan-Meier analysis and log-rank test were performed to evaluate the relationship between MICB and overall survival. Univariate and multivariate cox regression analyses were performed to identify the independent prognostic factors.

Results

High MICB was significantly associated with non-mucinous histological type (p < 0.001) and ≤4.0cm tumor size (p = 0.001). Kaplan-Meier analyses and log-rank test showed high MICB group had a better overall survival (p = 0.002). In cox regression analyses of Zhongshan cohort, MICB was confirmed as an independent prognostic factor of OS (p = 0.008, HR = 0.741, 95% CI = 0.594-0.924).

Conclusions

MICB was identified as a new independent prognostic factor in stage one to stage four CRC patients. CRC with high MICB expression conferred survival benefit.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Zhongshan Hospital, Fudan University, Shanghai, China.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.